| 11. |
- Lee, C.K., et al.
(author)
-
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
- 2011
-
In: British Journal of Cancer. - : Cancer Research UK. - 0007-0920 .- 1532-1827. ; 105:8, s. 1144-1150
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Patients with platinum-sensitive recurrent ovarian cancer are a heterogeneous group, and it is not possible to accurately predict the progression-free survival (PFS) in these patients. We developed and validated a nomogram to help improve prediction of PFS in patients treated with platinum-based chemotherapy. METHODS: The nomogram was developed in a training cohort (n = 955) from the CALYPSO trial and validated in the AGO-OVAR 2.5 Study (n = 340). The proportional-hazards model (nomogram) was based on pre-treatment characteristics. RESULTS: The nomogram had a concordance index (C-index) of 0.645. Significant predictors were tumour size platinum-chemotherapy-free interval, CA-125, number of organ metastatic sites and white blood count. When the nomogram was applied without CA-125 (CA-125 was not available in validation cohort), the C-indices were 0.624 (training) and 0.594 (validation). When classification was based only on the platinum-chemotherapy-free interval, the indices were 0.571 (training) and 0.560 (validation). The calibration plot in the validation cohort based on four predictors (without CA-125) suggested good agreement between actual and nomogram-predicted 12-month PFS probabilities. CONCLUSION: This nomogram, using five pre-treatment characteristics, improves prediction of PFS in patients with platinum-sensitive ovarian cancer having platinum-based chemotherapy. It will be useful for the design and stratification of patients in clinical trials and also for counselling patients.
|
|
| 12. |
- Michalowski, M. J., et al.
(author)
-
Spatially-resolved dust properties of the GRB 980425 host galaxy
- 2014
-
In: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 562, s. A70-
-
Journal article (peer-reviewed)abstract
- Gamma-ray bursts (GRBs) have been proposed as a tool for studying star formation in the Universe, so it is crucial to investigate whether their host galaxies and immediate environments are in any way special compared with other star-forming galaxies. Here we present spatially resolved maps of dust emission of the host galaxy of the closest known GRB 980425 at z = 0.0085 using our new high-resolution observations from Herschel, Atacama Pathfinder Experiment (APEX), Atacama Large Millimeter Array (ALMA) and Australia Telescope Compact Array (ATCA). We modelled the spectral energy distributions of the host and of the star-forming region displaying the Wolf-Rayet signatures in the spectrum (WR region), located 800 pc from the GRB position. The host is characterised by low dust content and a high fraction of UV-visible star formation, similar to other dwarf galaxies. These galaxies are abundant in the local universe, so it is not surprising to find a GRB in one of them, assuming the correspondence between the GRB rate and star formation. The WR region contributes substantially to the host emission at the far-infrared, millimetre, and radio wavelengths and we propose that this is a consequence of its high gas density. If dense environments are also found close to the positions of other GRBs, then the ISM density should also be considered, along with metallicity, an important factor influencing whether a given stellar population can produce a GRB.
|
|
| 13. |
- Pourovskii, L.V., et al.
(author)
-
Theoretical Prediction and Spectroscopic Fingerprints of an Orbital Transition in CeCu2Si2
- 2014
-
In: Physical Review Letters. - : American Physical Society. - 0031-9007 .- 1079-7114. ; 112:10, s. 106407-
-
Journal article (peer-reviewed)abstract
- We show that the heavy-fermion compound CeCu2Si2 undergoes a transition between two regimes dominated by different crystal-field states. At low pressure P and low temperature T the Ce 4f electron resides in the atomic crystal-field ground state, while at high P or T, the electron occupancy and spectral weight is transferred to an excited crystal-field level that hybridizes more strongly with itinerant states. These findings result from first-principles dynamical-mean-field-theory calculations. We predict experimental signatures of this orbital transition in x-ray spectroscopy. The corresponding fluctuations may be responsible for the second high-pressure superconducting dome observed in this and similar materials.
|
|
| 14. |
- Pujade-Lauraine, Eric, et al.
(author)
-
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
- 2010
-
In: Journal of Clinical Oncology. - : American Society of Clinical Oncology. - 0732-183X .- 1527-7755. ; 28:20, s. 3323-3329
-
Journal article (peer-reviewed)abstract
- PURPOSE: This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-sensitive relapsed/recurrent ovarian cancer (ROC).PATIENTS AND METHODS: Patients with histologically proven ovarian cancer with recurrence more than 6 months after first- or second-line platinum and taxane-based therapies were randomly assigned by stratified blocks to CD (carboplatin area under the curve [AUC] 5 plus PLD 30 mg/m(2)) every 4 weeks or CP (carboplatin AUC 5 plus paclitaxel 175 mg/m(2)) every 3 weeks for at least 6 cycles. Primary end point was progression-free survival (PFS); secondary end points were toxicity, quality of life, and overall survival.RESULTS: Overall 976 patients were recruited. With median follow-up of 22 months, PFS for the CD arm was statistically superior to the CP arm (hazard ratio, 0.821; 95% CI, 0.72 to 0.94; P = .005); median PFS was 11.3 versus 9.4 months, respectively. Although overall survival data are immature for final analysis, we report here a total of 334 deaths. Overall severe nonhematologic toxicity (36.8% v 28.4%; P < .01) leading to early discontinuation (15% v 6%; P < .001) occurred more frequently in the CP arm. More frequent grade 2 or greater alopecia (83.6% v 7%), hypersensitivity reactions (18.8% v 5.6%), and sensory neuropathy (26.9% v 4.9%) were observed in the CP arm; more hand-foot syndrome (grade 2 to 3, 12.0% v 2.2%), nausea (35.2% v 24.2%), and mucositis (grade 2-3, 13.9% v 7%) in the CD arm.CONCLUSION: To our knowledge, this trial is the largest in recurrent ovarian cancer and has demonstrated superiority in PFS and better therapeutic index of CD over standard CP.
|
|
